Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma.

Zöllner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, Parks S, Haladyna JN, Erkizan HV, Dirksen U, Hogarty MD, Üren A, Toretsky JA.

Sci Signal. 2017 Oct 3;10(499). pii: eaam8429. doi: 10.1126/scisignal.aam8429.


Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia.

Campbell CT, Haladyna JN, Drubin DA, Thomson TM, Maria MJ, Yamauchi T, Waters NJ, Olhava EJ, Pollock RM, Smith JJ, Copeland RA, Blakemore SJ, Bernt KM, Daigle SR.

Mol Cancer Ther. 2017 Aug;16(8):1669-1679. doi: 10.1158/1535-7163.MCT-16-0693. Epub 2017 Apr 20.


Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy.

Haladyna JN, Pastuer T, Riedel SS, Perraud AL, Bernt KM.

Exp Hematol. 2016 Jul;44(7):596-602.e3. doi: 10.1016/j.exphem.2016.03.006. Epub 2016 Mar 24.


MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.

Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM.

J Clin Invest. 2016 Apr 1;126(4):1438-50. doi: 10.1172/JCI80825. Epub 2016 Feb 29.


Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia.

Danis E, Yamauchi T, Echanique K, Zhang X, Haladyna JN, Riedel SS, Zhu N, Xie H, Orkin SH, Armstrong SA, Bernt KM, Neff T.

Cell Rep. 2016 Mar 1;14(8):1953-65. doi: 10.1016/j.celrep.2016.01.064. Epub 2016 Feb 18.


Epigenetic modifiers in normal and malignant hematopoiesis.

Haladyna JN, Yamauchi T, Neff T, Bernt KM.

Epigenomics. 2015;7(2):301-20. doi: 10.2217/epi.14.88. Review.


Supplemental Content

Loading ...
Support Center